RenovoRx engages Oklahoma University as clinical site for CouGar trial

RenovoRx announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial. The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma, or eCCA. The pivotal Phase III CouGar study is a randomized study designed to evaluate the safety and efficacy of unresectable, locally advanced eCCA using intravenous cisplatin, gemcitabine, and durvalumab versus Trans-Arterial Micro-Perfusion via RenovoGem with intravenous durvalumab. Oklahoma University Health is the first clinical site for the CouGar study.